Genetic variation in peroxisome proliferator-activated receptor gamma, soy, and mammographic density in Singapore Chinese women

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 4, 2012, Pages 635-644

  Lee, Eunjung ^a   Hsu, Chris ^a   Van Den Berg, David ^a   Ursin, Giske ^a,b   Koh, Woon Puay ^c   Yuan, Jian Min ^d   Stram, Daniel O ^a   Yu, Mimi C ^e   Wu, Anna H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CHINESE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIETARY INTAKE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; MAMMOGRAPHY; POPULATION RESEARCH; PRIORITY JOURNAL; SINGAPORE; SINGLE NUCLEOTIDE POLYMORPHISM; SOYBEAN; STATISTICAL SIGNIFICANCE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST; BREAST NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PPAR GAMMA; RISK FACTORS; SINGAPORE; SOY FOODS;

EID: 84859417962     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-1042     Document Type: Article

References (54)

1. Sharma AM, Staels B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007;92:386-95.
2. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997;99:2416-22. (Pubitemid 27227719)
3. Lefebvre M, Paulweber B, Fajas L, Woods J, McCrary C, Colombel JF, et al. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol 1999;162:331-40. (Pubitemid 29447426)
4. Ricketts ML, Moore DD, Banz WJ, Mezei O, Shay NF. Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J Nutr Biochem 2005;16:321-30. (Pubitemid 40776040)
5. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000;60:1604-8. (Pubitemid 30183431)
6. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
7. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998;1:465-70. (Pubitemid 128378895)
8. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, et al. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999;59:5671-3.
9. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000;92:418-23. (Pubitemid 30154824)
10. Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, et al. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 2004;18:528-40. (Pubitemid 38372810)
11. Tian L, Zhou J, Casimiro MC, Liang B, Ojeifo JO, Wang M, et al. Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. Cancer Res 2009;69:9236-44.
12. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-7. (Pubitemid 28507675)
13. Koh WP, Yuan JM, Van Den Berg D, Ingles SA, Yu MC. Peroxisome proliferator-activated receptor (PPAR) gamma gene polymorphisms and colorectal cancer risk among Chinese in Singapore. Carcinogenesis 2006;27:1797-802. (Pubitemid 44288662)
14. Memisoglu A, Hankinson SE, Manson JE, Colditz GA, Hunter DJ. Lack of association of the codon 12 polymorphism of the peroxisome proliferator- activated receptor gamma gene with breast cancer and body mass. Pharmacogenetics 2002;12:597-603. (Pubitemid 36005668)
15. Vogel U, Christensen J, Nexo BA, Wallin H, Friis S, Tjonneland A. Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 2007;28:427-34. (Pubitemid 46321860)
16. Chen F, Wilkens LR, Monroe KR, Stram DO, Kolonel LN, Henderson BE, et al. No association of risk variants for diabetes and obesity with breast cancer: the Multiethnic Cohort and PAGE studies. Cancer Epidemiol Biomarkers Prev 2011;20:1039-42.
17. Wu MH, Chu CH, Chou YC, Chou WY, Yang T, Hsu GC, et al. Joint effect of peroxisome proliferator-activated receptor gamma genetic polymorphisms and estrogen-related risk factors on breast cancer risk: results from a case-control study in Taiwan. Breast Cancer Res Treat 2011;127:777-84.
18. Wang Y, McCullough ML, Stevens VL, Rodriguez C, Jacobs EJ, Teras LR, et al. Nested case-control study of energy regulation candidate gene single nucleotide polymorphisms and breast cancer. Anticancer Res 2007;27:589-93. (Pubitemid 46374981)
19. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-4. (Pubitemid 47014500)
20. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007;39:865-9. (Pubitemid 47014497)
21. Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 2009;41:324-8.
22. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010;42:504-7.
23. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
24. Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J, et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A 2008;105:4340-5. (Pubitemid 351754382)
25. Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, Walker K, et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst 2011;103:425-35.
26. Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, Platte R, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 2009;41:585-90.
27. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159-69.
28. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 2002;347:886-94.
29. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, PikeMC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7. (Pubitemid 36124293)
30. Lindstrom S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, et al. Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet 2011;43:185-7.
31. Villacorta L, Schopfer FJ, Zhang J, Freeman BA, Chen YE. PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond) 2009;116:205-18.
32. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer 2008;98:9-14.
33. Dong JY, Qin LQ. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat 2011;125:315-23.
34. Hooper L, Madhavan G, Tice JA, Leinster SJ, Cassidy A. Effects of isoflavones on breast density in pre- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Hum Reprod Update 2010;16:745-60.
35. Maskarinec G, Meng L. An investigation of soy intake and mammographic characteristics in Hawaii. Breast Cancer Res 2001;3:134-41. (Pubitemid 32266284)
36. Maskarinec G, Pagano I, Lurie G, Kolonel LN. A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2006;15:732-9.
37. Nagata C, Matsubara T, Fujita H, Nagao Y, Shibuya C, Kashiki Y, et al. Associations of mammographic density with dietary factors in Japanese women. Cancer Epidemiol Biomarkers Prev 2005;14:2877-80. (Pubitemid 43068819)
38. Jakes RW, Duffy SW, Ng FC, Gao F, Ng EH, Seow A, et al. Mammographic parenchymal patterns and self-reported soy intake in Singapore Chinese women. Cancer Epidemiol Biomarkers Prev 2002;11:608-13. (Pubitemid 34760818)
39. Wu AH, Ursin G, Koh WP, Wang R, Yuan JM, Khoo KS, et al. Green tea, soy, and mammographic density in Singapore Chinese women. Cancer Epidemiol Biomarkers Prev 2008;17:3358-65.
40. Ng EH, Ng FC, Tan PH, Low SC, Chiang G, Tan KP, et al. Results of intermediate measures from a population-based, randomized trial of mammographic screening prevalence and detection of breast carcinoma among Asian women: the Singapore Breast Screening Project. Cancer 1998;82:1521-8. (Pubitemid 28164999)
41. Ursin G, Sun CL, Koh WP, Khoo KS, Gao F, Wu AH, et al. Associations between soy, diet, reproductive factors, and mammographic density in Singapore Chinese women. Nutr Cancer 2006;56:128-35. (Pubitemid 46417671)
42. Hankin JH, Stram DO, Arakawa K, Park S, Low SH, Lee HP, et al. Singapore Chinese Health Study: development, validation, and calibration of the quantitative food frequency questionnaire. Nutr Cancer 2001;39:187-95. (Pubitemid 33694034)
43. Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR, et al. The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 1998;7:43-7. (Pubitemid 28087141)
44. Edlund CK, Lee WH, Li D, Van Den Berg DJ, Conti DV. Snagger: a user-friendly program for incorporating additional information for tagSNP selection. BMC Bioinformatics 2008;9:174.
45. The International HapMap Project. International HapMap Consortium. Nature. 2003 Dec 18;426(6968):789-96. PMID: 14685227. Available from: http://hapmap.ncbi.nlm.nih.gov
46. Conneely KN, Boehnke M. So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am J Hum Genet 2007;81:1158-68. (Pubitemid 350211447)
47. Zeggini E,Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007;316:1336-41. (Pubitemid 46871654)
48. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007;121:856-62. (Pubitemid 47106217)
49. McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005;97:1366-76. (Pubitemid 41487804)
50. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
51. Chlebowski RT, Kuller LH, Prentice RL, StefanickML, Manson JE, Gass M, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-87.
52. Woolcott CG, Maskarinec G, Haiman CA, Verheus M, Pagano IS, Le Marchand L, et al. Association between breast cancer susceptibility loci and mammographic density: the Multiethnic Cohort. Breast Cancer Res 2009;11:R10.
53. Crandall CJ, Sehl ME, Crawford SL, Gold EB, Habel LA, Butler LM, et al. Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women. Breast Cancer Res 2009;11:R51.
54. Maskarinec G, Lurie G, Williams AE, Le Marchand L. An investigation of mammographic density and gene variants in healthy women. Int J Cancer 2004;112:683-8. (Pubitemid 39425950)